Equity Profile

RPRX

Royalty Pharma plc

Health CarePharmaceuticals$25.0B

Aug5Wed

Pre-Earnings Brief

UpcomingQ4-2017Pre-Market9:00 AM EDT

Company Snapshot

Royalty Pharma plc is a healthcare company that specializes in acquiring royalties from pharmaceutical products. With a market cap of $25 billion, it plays a significant role in funding drug development and innovation in the pharmaceutical industry.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for shareholders.

$1.18

Revenue

Revenue figures provide insight into the company's sales performance and overall market demand for its royalty agreements.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma reported a loss of $0.04 per share, which was below expectations. The company did not provide specific guidance for future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report earnings that align closely with consensus estimates, reflecting cautious optimism in the market.

Bull Case

If the company can exceed the EPS and revenue estimates, it may signal strong underlying demand for its royalty agreements and boost investor confidence.

Bear Case

Conversely, if the earnings report shows continued losses or revenue falls short, it could raise concerns about the sustainability of its business model.

Key Metrics to Watch

EPS

$1.18

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for shareholders.

Revenue

$874M

Revenue figures provide insight into the company's sales performance and overall market demand for its royalty agreements.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.18?

A positive surprise in EPS could indicate improved profitability and boost investor sentiment.

How does the revenue of $874M compare to expectations?

Revenue performance is crucial for assessing the company's growth and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new royalty agreements, which could lead to a stronger-than-expected performance.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility.

Historical performance shows that the company has the potential to exceed expectations based on past trends.

Key Risk

If revenue comes in significantly above $874M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it may set the tone for future growth and investor confidence.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong profitability and positive momentum.

Bear Confirmed If

An EPS below $1.15 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

The options market is pricing in a significant move following the earnings report, indicating uncertainty among investors.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests a potential average 1-day move of +2.89%, confirming a bullish outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted reactions as investors reassess their outlook.

Miss

A miss could lead to a decline, with historical averages suggesting a potential drop of around 5.53%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships.
2Insights into the company's strategy for acquiring new royalties.
3Management's outlook on market conditions and their impact on revenue.
4Comments on cost management and profitability improvements.
5Any guidance on future earnings or revenue expectations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for shareholders.

$1.18

Revenue

Revenue figures provide insight into the company's sales performance and overall market demand for its royalty agreements.

$874M

Wall Street expectations, options signals, track record, and call prep available with Pro.

RPRX Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

13%

Avg EPS Surprise

+5.28%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Royalty Pharma reported a loss of $0.04 per share, which was below expectations. The company did not provide specific guidance for future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Royalty Pharma to report earnings that align closely with consensus estimates, reflecting cautious optimism in the market.

Bull Case

If the company can exceed the EPS and revenue estimates, it may signal strong underlying demand for its royalty agreements and boost investor confidence.

Bear Case

Conversely, if the earnings report shows continued losses or revenue falls short, it could raise concerns about the sustainability of its business model.

Key Metrics to Watch

EPS

$1.18

Earnings per share is a key indicator of profitability and reflects the company's ability to generate profit for shareholders.

Revenue

$874M

Revenue figures provide insight into the company's sales performance and overall market demand for its royalty agreements.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $1.18?

A positive surprise in EPS could indicate improved profitability and boost investor sentiment.

How does the revenue of $874M compare to expectations?

Revenue performance is crucial for assessing the company's growth and market position.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the potential for revenue growth driven by new royalty agreements, which could lead to a stronger-than-expected performance.

Supporting Evidence

The options market is pricing a significant move, indicating that investors expect volatility.

Historical performance shows that the company has the potential to exceed expectations based on past trends.

Key Risk

If revenue comes in significantly above $874M, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it may set the tone for future growth and investor confidence.

Bull Confirmed If

An EPS of $1.20 or higher would confirm strong profitability and positive momentum.

Bear Confirmed If

An EPS below $1.15 would raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±12.3%

The options market is pricing in a significant move following the earnings report, indicating uncertainty among investors.

Detail

ATM IV

0.3%

30d HV

19.2%

Calls (25K)P/C Ratio: 0.01Puts (0)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

84.49%

of float

Insider

7.12%

of float

Holders

844

institutions

Top Holders· as of Dec 2025

Morgan Stanley
55,274,069 sh · $2.7B
12.44%
25.2%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Royalty Pharma beats expectations, history suggests a potential average 1-day move of +2.89%, confirming a bullish outlook.

In-Line / Cautious

If results are in line but management is cautious, the stock may see muted reactions as investors reassess their outlook.

Miss

A miss could lead to a decline, with historical averages suggesting a potential drop of around 5.53%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new royalty agreements or partnerships.
2Insights into the company's strategy for acquiring new royalties.
3Management's outlook on market conditions and their impact on revenue.
4Comments on cost management and profitability improvements.
5Any guidance on future earnings or revenue expectations.